Financials Shanghai RAAS Blood Products Co., Ltd.

Equities

002252

CNE100000C31

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 13/05/2024 am IST			5-day change	1st Jan Change
7.38 ^CNY	-0.81%		+0.68%	-7.75%

29/04	Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
29/04	RAAS Blood Products' 2023 Profit Falls 5% Despite 21% Revenue Growth	MT

Valuation

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	49,882	45,972	42,737	53,164	48,742	-	-
Enterprise Value (EV) ¹	49,882	45,972	42,737	53,164	48,742	48,742	48,742
P/E ratio	35.2 x	35.9 x	22.6 x	29.6 x	20.8 x	18.5 x	16.8 x
Yield	-	-	-	0.38%	0.54%	0.58%	-
Capitalization / Revenue	-	-	-	6.68 x	5.51 x	4.99 x	4.59 x
EV / Revenue	-	-	-	6.68 x	5.51 x	4.99 x	4.59 x
EV / EBITDA	-	-	-	22.2 x	18.4 x	16.7 x	14.8 x
EV / FCF	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-
Price to Book	-	-	-	1.79 x	1.51 x	1.4 x	1.29 x
Nbr of stocks (in thousands)	67,40,788	67,40,788	67,40,788	66,45,481	66,04,635	-	-
Reference price ²	7.400	6.820	6.340	8.000	7.380	7.380	7.380
Announcement Date	22/04/21	27/04/22	24/04/23	28/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	-	-	-	7,964	8,843	9,770	10,627
EBITDA ¹	-	-	-	2,395	2,644	2,923	3,283
EBIT ¹	-	-	-	2,225	2,728	3,139	3,617
Operating Margin	-	-	-	27.94%	30.85%	32.13%	34.04%
Earnings before Tax (EBT) ¹	-	-	-	2,204	2,714	3,125	3,603
Net income ¹	1,324	1,295	1,880	1,779	2,338	2,657	2,917
Net margin	-	-	-	22.34%	26.44%	27.19%	27.45%
EPS ²	0.2100	0.1900	0.2800	0.2700	0.3550	0.4000	0.4400
Free Cash Flow	-	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-
Dividend per Share ²	-	-	-	0.0300	0.0400	0.0430	-
Announcement Date	22/04/21	27/04/22	24/04/23	28/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4
Net sales ¹	-	2,029	2,056	2,215	2,284	2,226
EBITDA	-	-	-	-	-	-
EBIT	-	-	-	-	-	-
Operating Margin	-	-	-	-	-	-
Earnings before Tax (EBT)	-	-	-	-	-	-
Net income	548.6	-	-	-	-	-
Net margin	-	-	-	-	-	-
EPS ²	0.0820	-	0.1140	0.0900	0.1100	0.0600
Dividend per Share	-	-	-	-	-	-
Announcement Date	24/10/23	28/04/24	29/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Balance Sheet Analysis

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-
ROE (net income / shareholders' equity)	-	-	-	6.06%	7.33%	7.74%	7.7%
ROA (Net income/ Total Assets)	-	-	-	-	7.2%	7.3%	-
Assets ¹	-	-	-	-	32,477	36,392	-
Book Value Per Share ²	-	-	-	4.460	4.880	5.280	5.700
Cash Flow per Share ²	-	-	-	0.3400	0.1100	0.4700	0.0400
Capex ¹	-	-	-	448	40	20	10
Capex / Sales	-	-	-	5.63%	0.45%	0.2%	0.09%
Announcement Date	22/04/21	27/04/22	24/04/23	28/04/24	-	-	-

¹CNY in Million²CNY

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Shanghai RAAS Blood Products Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.38 CNY

Average target price

7 CNY

Spread / Average Target

-5.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.	-7.75%	673.94Cr
CSL LIMITED	-2.47%	8.94TCr
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	4.07TCr
BIOGEN INC.	-12.92%	3.28TCr
UCB	+53.49%	2.5TCr
BIOMARIN PHARMACEUTICAL INC.	-16.51%	1.53TCr
INCYTE CORPORATION	-8.27%	1.29TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.60%	1.16TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.82%	1.15TCr
SWEDISH ORPHAN BIOVITRUM AB	+5.54%	898.19Cr

Biopharmaceuticals